Christoph Neuwirth1, Paul E Barkhaus2, Christian Burkhardt1, José Castro3, David Czell4, Mamede de Carvalho3, Sanjeev Nandedkar5, Erik Stålberg6, Markus Weber7. 1. Neuromuscular Diseases Unit/ALS Clinic, Kantonsspital St.Gallen, St.Gallen, Switzerland. 2. Medical College of Wisconsin, Milwaukee, Wisconsin, USA. 3. Department of Neurosciences, Faculty of Medicine, Hospital de Santa Maria, Instituto de Medicina Molecular, University of Lisbon, Lisbon, Portugal. 4. Kantonsspital Winterthur, Winterthur, Switzerland. 5. Natus Medical Incorporated, Middleton, Wisconsin, USA. 6. Department of Clinical Neurophysiology, Institute of Neurosciences, Uppsala University, University Hospital, Uppsala, Sweden. 7. Neuromuscular Diseases Unit/ALS Clinic, Kantonsspital St.Gallen, St.Gallen, Switzerland Department of Neurology, University Hospital Basel, Basel, Switzerland.
Abstract
BACKGROUND: Motor Unit Number Index (MUNIX) is a novel neurophysiological measure that provides an index of the number of functional lower motor neurons in a given muscle. So far its performance across centres in patients with amyotrophic lateral sclerosis (ALS) has not been investigated. OBJECTIVE: To perform longitudinal MUNIX recordings in a set of muscles in a multicentre setting in order to evaluate its value as a marker of disease progression. METHODS: Three centres applied MUNIX in 51 ALS patients over 15 months. Six different muscles (abductor pollicis brevis, abductor digiti minimi, biceps brachii, tibialis anterior, extensor dig. brevis, abductor hallucis) were measured every 3 months on the less affected side. The decline between MUNIX and ALSFRS-R was compared. RESULTS: 31 participants reached month 12. For all participants, ALSFRS-R declined at a rate of 2.3%/month. Using the total score of all muscles, MUNIX declined significantly faster by 3.2%/month (p ≤ 0.02). MUNIX in individual muscles declined between 2.4% and 4.2%, which differed from ASLFRS-R decline starting from month 3 (p ≤ 0.05 to 0.002). Subgroups with bulbar, lower and upper limb onset showed different decline rates of ALSFRS-R between 1.9% and 2.8%/month, while MUNIX total scores showed similar decline rates over all subgroups. Mean intraclass correlation coefficient for MUNIX intra-rater reliability was 0.89 and for inter-rater reliability 0.80. CONCLUSION: MUNIX is a reliable electrophysiological biomarker to track lower motor neuron loss in ALS. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
BACKGROUND: Motor Unit Number Index (MUNIX) is a novel neurophysiological measure that provides an index of the number of functional lower motor neurons in a given muscle. So far its performance across centres in patients with amyotrophic lateral sclerosis (ALS) has not been investigated. OBJECTIVE: To perform longitudinal MUNIX recordings in a set of muscles in a multicentre setting in order to evaluate its value as a marker of disease progression. METHODS: Three centres applied MUNIX in 51 ALSpatients over 15 months. Six different muscles (abductor pollicis brevis, abductor digiti minimi, biceps brachii, tibialis anterior, extensor dig. brevis, abductor hallucis) were measured every 3 months on the less affected side. The decline between MUNIX and ALSFRS-R was compared. RESULTS: 31 participants reached month 12. For all participants, ALSFRS-R declined at a rate of 2.3%/month. Using the total score of all muscles, MUNIX declined significantly faster by 3.2%/month (p ≤ 0.02). MUNIX in individual muscles declined between 2.4% and 4.2%, which differed from ASLFRS-R decline starting from month 3 (p ≤ 0.05 to 0.002). Subgroups with bulbar, lower and upper limb onset showed different decline rates of ALSFRS-R between 1.9% and 2.8%/month, while MUNIX total scores showed similar decline rates over all subgroups. Mean intraclass correlation coefficient for MUNIX intra-rater reliability was 0.89 and for inter-rater reliability 0.80. CONCLUSION:MUNIX is a reliable electrophysiological biomarker to track lower motor neuron loss in ALS. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Authors: Christoph Neuwirth; Christian Burkhardt; James Alix; José Castro; Mamede de Carvalho; Malgorzata Gawel; Stephan Goedee; Julian Grosskreutz; Timothée Lenglet; Cristina Moglia; Taha Omer; Maarten Schrooten; Markus Weber Journal: PLoS One Date: 2016-05-02 Impact factor: 3.240